IYAMED Pharmaceuticals

Iyamed Pharmaceuticals is a biopharmaceutical company dedicated to developing novel small molecule drugs that target protein-protein interactions (PPIs) and induce protein degradation. Based in Rockville, Maryland, the company utilizes a proprietary platform to design Proteolysis-Targeting Chimeras (PROTACs) and molecular glues for high-value, traditionally undruggable targets in oncology and immunology. Their lead research programs focus on inhibiting and degrading key proteins such as MDM2 and STAT3 to treat various cancers and inflammatory conditions. By integrating structural biology with advanced medicinal chemistry, Iyamed aims to deliver transformative therapies for patients with significant unmet medical needs.